WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 571473
Description: D21-6076 is a β-1,6-Glucan inhibitor. These inhibitors work as antifungal drugs by targeting the fungal cell wall. As glucan is a major component of the cell wall, specifically β-1,6-Glucan, these drugs can help fight fungal infections by degrading glucan or stopping production by inhibiting its synthase. D21-6076 is a pyridobenzimidazole derivative that achieves this function, and is effective against Candida strains (even fluconazole-resistant strains). As an improvement to D75-4590, it is active orally.
MedKoo Cat#: 571473
Chemical Formula: C24H24N6
Exact Mass: 396.2062
Molecular Weight: 396.5
Elemental Analysis: C, 72.70; H, 6.10; N, 21.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: D21-6076; D216076; D21 6076
IUPAC/Chemical Name: 6-(3-(dimethylamino)pyrrolidin-1-yl)-8-methyl-7-phenylimidazo[1,2-a:4,5-b']dipyridine-9-carbonitrile
InChi Key: MRZRZGFKBHEXEA-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H24N6/c1-16-19(14-25)23-27-22-20(10-7-12-26-22)30(23)24(21(16)17-8-5-4-6-9-17)29-13-11-18(15-29)28(2)3/h4-10,12,18H,11,13,15H2,1-3H3
SMILES Code: N#CC1=C(C)C(C2=CC=CC=C2)=C(N3CC(N(C)C)CC3)N4C5=CC=CN=C5N=C41
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 396.5 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kitamura A, Higuchi S, Hata M, Kawakami K, Yoshida K, Namba K, Nakajima R. Effect of beta-1,6-glucan inhibitors on the invasion process of Candida albicans: potential mechanism of their in vivo efficacy. Antimicrob Agents Chemother. 2009 Sep;53(9):3963-71. doi: 10.1128/AAC.00435-09. Epub 2009 Jul 13. PubMed PMID: 19596881; PubMed Central PMCID: PMC2737848.
2: Kitamura A, Someya K, Okumura R, Hata M, Takeshita H, Nakajima R. In vitro antifungal activities of D11-2040, a beta-1,6-glucan inhibitor, with or without currently available antifungal drugs. Biol Pharm Bull. 2010;33(2):192-7. PubMed PMID: 20118539.
1: Liu N, Tu J, Dong G, Wang Y, Sheng C. Emerging New Targets for the Treatment of Resistant Fungal Infections. J Med Chem. 2018 Jan 16. doi:
10.1021/acs.jmedchem.7b01413. [Epub ahead of print] PubMed PMID: 29294275.
There is increasing morbidity and mortality resulting from invasive fungal infections (IFIs) and antifungal drug resistance. As a result, several drug therapies are addressing the need by discovering and designing new antifungal drug targets and mechanisms, specifically against the most common fungi causing IFIs: Candida, Cryptococcus, and Aspergillus species. Existing drugs (polyenes, azoles, and echinocandins) have limited clinical efficacy, narrow antifungal spectrum, unfavorable pharmacokinetic profiles, significant side effects, drug−drug interactions, and resistance issues.